Emina Emilia Torlakovic

Summary

Affiliation: University of Saskatchewan
Country: Canada

Publications

  1. pmc RIZ1 is potential CML tumor suppressor that is down-regulated during disease progression
    Ashakumary Lakshmikuttyamma
    Cancer Stem Cell Research Group, University of Saskatchewan, Saskatoon, SK, Canada
    J Hematol Oncol 2:28. 2009
  2. ncbi Sessile serrated adenoma: a brief history and current status
    Emina Torlakovic
    Department of Pathology, College of Medicine, Royal University Hospital, University of Saskatchewan, Saskatoon, Canada
    Crit Rev Oncog 12:27-39. 2006
  3. ncbi Prognostic significance of PU.1 in follicular lymphoma
    E E Torlakovic
    Department of Pathology, Royal University Hospital Saskatoon, Canada
    J Pathol 209:352-9. 2006
  4. ncbi A marginal zone phenotype in follicular lymphoma with t(14;18) is associated with secondary cytogenetic aberrations typical of marginal zone lymphoma
    E E Torlakovic
    Department of Pathology, College of Medicine, University of Saskatchewan, Royal University Hospital, Saskatoon, SK, Canada
    J Pathol 209:258-64. 2006
  5. pmc Cyclophilin C-associated protein (CyCAP) knock-out mice spontaneously develop colonic mucosal hyperplasia and exaggerated tumorigenesis after treatment with carcinogen azoxymethane
    Emina Emilia Torlakovic
    Department of Pathology, Royal University Hospital, College of Medicine, University of Saskatchewan, Saskatoon, Canada
    BMC Cancer 9:251. 2009
  6. ncbi Differential expression of steroid receptors in prostate tissues before and after radiation therapy for prostatic adenocarcinoma
    Emina Torlakovic
    Department of Pathology, The Norwegian Radium Hospital, University of Oslo, Oslo, Norway
    Int J Cancer 117:381-6. 2005
  7. ncbi PU.1 protein expression has a positive linear association with protein expression of germinal centre B cell genes including BCL-6, CD10, CD20 and CD22: identification of PU.1 putative binding sites in the BCL-6 promotor
    Emina Torlakovic
    Department of Pathology, The Norwegian Radium Hospital, University of Oslo, Oslo, Norway
    J Pathol 206:312-9. 2005
  8. ncbi Fli-1 expression in malignant melanoma
    Emina E Torlakovic
    Department of Pathology, Royal University Hospital, Saskatoon, SK, Canada
    Histol Histopathol 23:1309-14. 2008
  9. doi Biological effects induced by insulin-like growth factor binding protein 3 (IGFBP-3) in malignant melanoma
    Geir Frode Oy
    Department of Tumor Biology, Institute for Cancer Research, Oslo, Norway
    Int J Cancer 126:350-61. 2010
  10. ncbi Pax-5 expression in nonhematopoietic tissues
    Emina Torlakovic
    Department of Laboratory Medicine and Pathology, Royal University Hospital, College of Medicine, University of Saskatchewan, Saskatoon, Canada
    Am J Clin Pathol 126:798-804. 2006

Collaborators

Detail Information

Publications15

  1. pmc RIZ1 is potential CML tumor suppressor that is down-regulated during disease progression
    Ashakumary Lakshmikuttyamma
    Cancer Stem Cell Research Group, University of Saskatchewan, Saskatoon, SK, Canada
    J Hematol Oncol 2:28. 2009
    ..In CML blast crisis cell lines RIZ1 represses insulin-like growth factor-1 expression and autocrine signaling. Together these observations suggest that RIZ1 may have a role in the chronic phase to blast crisis transition in CML...
  2. ncbi Sessile serrated adenoma: a brief history and current status
    Emina Torlakovic
    Department of Pathology, College of Medicine, Royal University Hospital, University of Saskatchewan, Saskatoon, Canada
    Crit Rev Oncog 12:27-39. 2006
    ..This review describes the history of morphologic discovery of SSA and reports on current status of this lesion...
  3. ncbi Prognostic significance of PU.1 in follicular lymphoma
    E E Torlakovic
    Department of Pathology, Royal University Hospital Saskatoon, Canada
    J Pathol 209:352-9. 2006
    ....
  4. ncbi A marginal zone phenotype in follicular lymphoma with t(14;18) is associated with secondary cytogenetic aberrations typical of marginal zone lymphoma
    E E Torlakovic
    Department of Pathology, College of Medicine, University of Saskatchewan, Royal University Hospital, Saskatoon, SK, Canada
    J Pathol 209:258-64. 2006
    ..002, p=0.037, p=0.039, respectively, two-sided Fisher's exact test)...
  5. pmc Cyclophilin C-associated protein (CyCAP) knock-out mice spontaneously develop colonic mucosal hyperplasia and exaggerated tumorigenesis after treatment with carcinogen azoxymethane
    Emina Emilia Torlakovic
    Department of Pathology, Royal University Hospital, College of Medicine, University of Saskatchewan, Saskatoon, Canada
    BMC Cancer 9:251. 2009
    ..Cyclophilin C-associated protein (CyCAP) has been described to down-modulate endotoxin signaling in colorectal murine mucosa and is a murine orthologue of the tumor-associated antigen 90 K (TAA90K)/mac-2-binding protein...
  6. ncbi Differential expression of steroid receptors in prostate tissues before and after radiation therapy for prostatic adenocarcinoma
    Emina Torlakovic
    Department of Pathology, The Norwegian Radium Hospital, University of Oslo, Oslo, Norway
    Int J Cancer 117:381-6. 2005
    ..Although stromal AR was doubled after RT, the tumor and benign epithelium expression of AR seemed resistant to change by RT...
  7. ncbi PU.1 protein expression has a positive linear association with protein expression of germinal centre B cell genes including BCL-6, CD10, CD20 and CD22: identification of PU.1 putative binding sites in the BCL-6 promotor
    Emina Torlakovic
    Department of Pathology, The Norwegian Radium Hospital, University of Oslo, Oslo, Norway
    J Pathol 206:312-9. 2005
    ..Our findings support the contention that PU.1 may also have an important role in GC B cell development...
  8. ncbi Fli-1 expression in malignant melanoma
    Emina E Torlakovic
    Department of Pathology, Royal University Hospital, Saskatoon, SK, Canada
    Histol Histopathol 23:1309-14. 2008
    ..267, p=0.030, Spearman correlation). Therefore, the expression of Fli-1 in malignant melanoma appears to be associated with biologically more aggressive tumors...
  9. doi Biological effects induced by insulin-like growth factor binding protein 3 (IGFBP-3) in malignant melanoma
    Geir Frode Oy
    Department of Tumor Biology, Institute for Cancer Research, Oslo, Norway
    Int J Cancer 126:350-61. 2010
    ..Development of resistance to the antiproliferative effects of IGFBP-3 may be an important step in progression of malignant melanomas...
  10. ncbi Pax-5 expression in nonhematopoietic tissues
    Emina Torlakovic
    Department of Laboratory Medicine and Pathology, Royal University Hospital, College of Medicine, University of Saskatchewan, Saskatoon, Canada
    Am J Clin Pathol 126:798-804. 2006
    ....
  11. ncbi Phorbol ester phorbol-12-myristate-13-acetate promotes anchorage-independent growth and survival of melanomas through MEK-independent activation of ERK1/2
    Kjersti Jørgensen
    Department of Pathology, The Norwegian Radium Hospital, HF, 0310 Oslo, Norway
    Biochem Biophys Res Commun 329:266-74. 2005
    ....
  12. ncbi Expression of activated Akt and PTEN in malignant melanomas: relationship with clinical outcome
    Ana Slipicevic
    Department of Pathology, The Norwegian Radium Hospital, University of Oslo, Oslo, Norway
    Am J Clin Pathol 124:528-36. 2005
    ..025) for patients with superficial spreading melanoma...
  13. ncbi Sessile serrated adenoma (SSA) vs. traditional serrated adenoma (TSA)
    Emina Emilia Torlakovic
    Department of Pathology, Royal University Hospital, University of Saskatchewan, Saskatoon, SK, Canada
    Am J Surg Pathol 32:21-9. 2008
    ....
  14. doi Implementation of a Canadian external quality assurance program for breast cancer biomarkers: an initiative of Canadian Quality Control in immunohistochemistry (cIQc) and Canadian Association of Pathologists (CAP) National Standards Committee/Immunohistoc
    Jefferson Terry
    Department of Pathology, Vancouver General Hospital and University of British Columbia, Vancouver, Canada
    Appl Immunohistochem Mol Morphol 17:375-82. 2009
    ....
  15. doi [Molecular diagnosis of malignant lymphomas]
    Harald Holte
    Kreftklinikken, Oslo universitetssykehus, Radiumhospitalet, Oslo, Norway
    Tidsskr Nor Laegeforen 129:2352-6. 2009
    ..This article describes experimental molecular diagnostics, mainly based on microarray-based gene expression technology...